Patents by Inventor Huaizhong Hu
Huaizhong Hu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11834716Abstract: Disclosed is a method for predicting whether esophageal cancer is sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody. Specifically, the method predicts by measurement of expression at the RNA level, or at the protein level, of at least one biomarker selected from SDC2, PTGES, NCF2, NOXA1, CARD6 and GNAZ in a tumor sample.Type: GrantFiled: June 12, 2018Date of Patent: December 5, 2023Assignee: Canbridge Life Sciences LTDInventors: James Qun Xue, Jing Wang, Ya Gao, Huaizhong Hu
-
Publication number: 20220259152Abstract: The present disclosure relates to the field of pharmaceutical technology, providing three crystalline forms, i.e., a crystalline form AB, a crystalline form M and a crystalline form F, of the compound 6-[[4-[2-fluoro-4-[[1-[(4-fluorophenyl)aminoformyl]cyclopropanecarbonyl]-amino]phenoxy]-6-methoxy-7-quinolyl]oxy]hexanoic acid for treatment of diseases related to protein kinases AXL and/or VEGFR2. The present disclosure also provides methods for preparing these three crystalline forms and pharmaceutical compositions comprising these three crystalline forms. The crystalline form AB, the crystalline form M and the crystalline form F of the present disclosure all have good chemical stability, and the preparation processes of the three crystalline forms of the present disclosure are simple for implementation with high product yield and purity, allowing stable and mass production that facilitates promotion and application.Type: ApplicationFiled: April 20, 2020Publication date: August 18, 2022Applicant: Beijing Konruns Pharmaceutical Co., Ltd.Inventors: Xiaohua SUN, Long WANG, Hongzhen YANG, Huaizhong HU
-
Publication number: 20210025006Abstract: The invention discloses a method for predicting whether esophageal cancer is sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody. Specifically, the method predicts by measurement of expression at the RNA level, or at the protein level, of at least one biomarker selected from SDC2, PTGES, NCF2, NOXA1, CARD6 and GNAZ in a tumor sample.Type: ApplicationFiled: June 12, 2018Publication date: January 28, 2021Inventors: James Qun Xue, Jing Wang, Ya Gao, Huaizhong Hu
-
Patent number: 10060930Abstract: The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney disorders.Type: GrantFiled: January 4, 2016Date of Patent: August 28, 2018Assignee: Renovar IncorporatedInventors: Huaizhong Hu, Stuart Knechtle
-
Publication number: 20160116484Abstract: The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney disorders.Type: ApplicationFiled: January 4, 2016Publication date: April 28, 2016Inventors: Huaizhong HU, Stuart KNECHTLE
-
Patent number: 9229011Abstract: The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney disorders.Type: GrantFiled: April 20, 2012Date of Patent: January 5, 2016Assignee: RENOVAR INCORPORATEDInventors: Huaizhong Hu, Stuart Knechtle
-
Patent number: 8987426Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.Type: GrantFiled: April 10, 2012Date of Patent: March 24, 2015Assignees: The United States of America, as represented by the Secretary, Department of Health & Human Services, Novartis AGInventors: David M. Neville, Jr., Jerry T. Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
-
Publication number: 20150011419Abstract: The present invention provides systems and methods for characterizing biological markers in the urine of systemic lupus erythematosus (SLE) subjects. In particular, the present invention relates to the detection of cytokines and chemokines in urine of SLE subjects for determining nephritic disease states and kidney damage in SLE subjects and the efficacy of agents and interventions used to treat lupus nephritis.Type: ApplicationFiled: September 25, 2014Publication date: January 8, 2015Inventors: Ganesh Vasudevan, Huaizhong Hu, Stuart Knechtle
-
Publication number: 20130211049Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be ex-pressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.Type: ApplicationFiled: April 10, 2012Publication date: August 15, 2013Applicants: Office of Technology TransferInventors: David M. Neville, JR., Jerry T. Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
-
Publication number: 20120208717Abstract: The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney disorders.Type: ApplicationFiled: April 20, 2012Publication date: August 16, 2012Applicant: RENOVAR INCORPORATEDInventors: Huaizhong Hu, Stuart Knechtle
-
Patent number: 8217158Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.Type: GrantFiled: March 5, 2010Date of Patent: July 10, 2012Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: David M. Neville, Jr., Jerry Todd Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
-
Publication number: 20110236912Abstract: The present invention provides systems and methods for characterizing biological markers in the urine of systemic lupus erythematosus (SLE) subjects. In particular, the present invention relates to the detection of cytokines and chemokines in urine of SLE subjects for determining nephritic disease states and kidney damage in SLE subjects and the efficacy of agents and interventions used to treat lupus nephritis.Type: ApplicationFiled: November 3, 2009Publication date: September 29, 2011Applicant: Renovar, Inc.Inventors: Ganesh Vasudevan, Huaizhong Hu, Stuart Knechtle
-
Publication number: 20110086416Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.Type: ApplicationFiled: March 5, 2010Publication date: April 14, 2011Applicant: The Government of the US, as Represented by the Secretary, Department of Health and Human ServicesInventors: David M. Neville, Jr., Jerry Todd Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
-
Patent number: 7696338Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein.Type: GrantFiled: May 18, 2001Date of Patent: April 13, 2010Assignees: The United States of America as represented by the Department of Health and Human Services, Novartis AGInventors: David M. Neville, Jr., Jerry T. Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
-
Publication number: 20090197287Abstract: The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney disorders.Type: ApplicationFiled: December 8, 2008Publication date: August 6, 2009Applicant: RENOVAR INCORPORATEDInventors: Huaizhong Hu, Stuart Knechtle
-
Patent number: 7531301Abstract: The present invention relates to methods of diagnosing and predicting organ transplant rejection. In particular, the present invention relates to the detection and prediction of kidney transplant rejection by detection of CXCR3 and CCL chemokines in urine. The present invention provides improved methods of diagnosing organ rejection and determining the efficacy of anti-rejection drugs.Type: GrantFiled: July 17, 2007Date of Patent: May 12, 2009Assignee: RenovarInventors: Huaizhong Hu, Alice Puchalaki
-
Patent number: 7517527Abstract: Provided is a method of treating an autoimmune disease in an animal comprising administering to the animal an antibody-DT mutant immunotoxin which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the autoimmune disease is treated. In a further embodiment, the invention provides a method of treating T cell leukemias or lymphomas in an animal comprising administering to the animal an antibody-DT mutant immunotoxin which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the T cell leukemias or lymphomas are treated.Type: GrantFiled: September 3, 1999Date of Patent: April 14, 2009Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: David M. Neville, Jr., Jerry Todd Thompson, Huaizhong Hu, Shenglin Ma
-
Patent number: 7476497Abstract: The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney disorders.Type: GrantFiled: November 21, 2006Date of Patent: January 13, 2009Assignee: Renovar IncorporatedInventors: Huaizhong Hu, Stuart Knechtle
-
Publication number: 20080206794Abstract: The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of contrast-induced nephropathy by detection of cytokines, cytokine-related compounds, and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat contrast-induce nephropathy.Type: ApplicationFiled: September 17, 2007Publication date: August 28, 2008Applicant: Renovar IncorporatedInventors: Huaizhong Hu, Stuart Knechtle
-
Publication number: 20070287188Abstract: The present invention relates to methods of diagnosing and predicting organ transplant rejection. In particular, the present invention relates to the detection and prediction of kidney transplant rejection by detection of CXCR3 and CCL chemokines in urine. The present invention provides improved methods of diagnosing organ rejection and determining the efficacy of anti-rejection drugs.Type: ApplicationFiled: July 17, 2007Publication date: December 13, 2007Inventors: Huaizhong Hu, Alice Puchalaki